医学
肝移植
公共卫生
肝病
心理干预
环境卫生
脂肪性肝炎
医疗保健
肝硬化
疾病
肝细胞癌
全球卫生
脂肪肝
梅德林
家庭医学
不利影响
重症监护医学
老年学
移植
2型糖尿病
卫生政策
糖尿病
疾病负担
护理部
作者
Zobair M. Younossi,Vincent Wai‐Sun Wong,Emmanuel Tsochatzis,Laurent Castéra,Michael Betel,Linda Henry,Shira Zelber‐Sagi
摘要
Metabolic dysfunction-associated steatotic liver disease (MASLD) is growing in prevalence around the world, with a current global prevalence rate of 38%. Although MASLD serves as an umberlla term, its subtype of metabolic dysfunction associated steatohepatitis (MASH) with a prevalence of 5-7%, can lead to adverse liver outcomes including cirrhosis and liver mortality. However, prevalence rates for MASLD/MASH vary by country and region of the world. With the increasing rates of type 2 diabetes and obesity, MASLD/MASH is increasing and is currently among the top causes of hepatocellular carcinoma and an indication for liver transplantation in the United States. Therefore, the care model is shifting to prevention given this large clinical, economic and humanistic burden of this liver disease. As in other noncommunicable diseases, interventional priorities for policymakers should be focused on building infrastructure that supports physical activity and healthy food choices as well as access to approved treatments for MASLD. At the same time, identifying individuals at risk for adverse outcomes using non-invasive tests and developing individual care plans that address the needs of each patient with MASLD, including their mental and physical health, should be a focus for healthcare providers. Furthermore, raising awareness among patients, the public and healthcare providers continues to be a crucial need. This report will provide recommendations for policymakers to provide the needed interventions to reverse the current trajectory of this liver disease.
科研通智能强力驱动
Strongly Powered by AbleSci AI